Go Deep
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,538 | -1.4 | 0.62 | 0.01 | 738.06 |
| Oct 2026 | 21,561 | -1.4 | 0.61 | 0.01 | 729.20 |
| Oct 2026 | 21,514 | -1.5 | 0.62 | 0.01 | 742.60 |
| Oct 2026 | 21,565 | -1.4 | 0.61 | 0.01 | 726.46 |
| Oct 2026 | 21,585 | -1.4 | 0.61 | 0.01 | 721.55 |
| Oct 2026 | 21,460 | -1.5 | 0.64 | 0.01 | 756.63 |
| Oct 2026 | 21,453 | -1.5 | 0.64 | 0.01 | 756.66 |
| Oct 2026 | 21,399 | -1.5 | 0.65 | 0.01 | 770.23 |
Atrium Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3,004,000.0 | 19,635,000.0 | 859,000.0 | 12,339,000.0 |
| Net Profit | -20,186,000.0 | -16,633,000.0 | -48,069,000.0 | -8,287,000.0 |
| EPS | -1.2 | -1.0 | — | — |
Atrium Therapeutics, Inc. Revenue & Profit: Last 3 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 18,618,000.0 | 10,897,000.0 | 9,764,000.0 |
| Net Profit | -76,684,000.0 | -25,122,000.0 | -6,385,000.0 |
| EPS | -2.9 | -1.5 | -0.4 |
Atrium Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Total Assets | 278,353,000.0 | 7,186,000.0 | 10,293,000.0 |
| Total Liabilities | 71,066,000.0 | 68,294,000.0 | 80,912,000.0 |
| Total Equity | 207,287,000.0 | -61,108,000.0 | -70,619,000.0 |
Owes vs Owns
Atrium Therapeutics, Inc. owed $0.24 for every $1 it owned in Jun 2026, down from $7.86 in Dec 2023.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.24× | 0.26× | 9.50× | 7.86× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Atrium Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 97.0%Fixed assets (tangible) 2.0%Other assets 1.0%
How it's funded — Dec 2025
Short-term debt 1.3%Payables 1.6%Other liabilities 22.6%Shareholders' equity 74.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | 270.0 | 0.0 | 0.0 |
| Receivables | 0.0 | 0.0 | 0.8 |
| Inventory | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 5.5 | 6.7 | 9.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 |
| Other assets | 2.8 | 0.5 | 0.1 |
| Liabilities & equity | |||
| Short-term debt | 3.7 | 3.8 | 3.6 |
| Long-term debt | 0.0 | 3.0 | 6.2 |
| Payables | 4.4 | 0.5 | 0.5 |
| Other liabilities | 63.0 | 61.0 | 70.6 |
| Shareholders' equity | 207.3 | -61.1 | -70.6 |
| Net tangible assets | 207.3 | -61.1 | -70.6 |
Atrium Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Operating Activities | -41,129,000.0 | -22,553,000.0 | 56,390,000.0 |
| Investing Activities | -1,445,000.0 | -266,000.0 | -320,000.0 |
| Financing Activities | 42,574,000.0 | 22,819,000.0 | -56,070,000.0 |